Kane Biotech’s Coactiv+™ Technology Could Address a Pricey and Painful Problem: Lack of Healing in Chronic Wounds Due to Microbial Biofilm Formation Feb 6, 2023
Kane Biotech Announces First Distribution Agreement for its coactiv+™ Antimicrobial Hydrogel Jan 4, 2023
Kane Biotech to Release Third Quarter 2022 Financial Results on November 24, 2022 – Conference Call to Follow Nov 17, 2022
Kane Biotech Receives an Additional $425K USD of Funding for its DispersinB® Hydrogel from the United States Department of Defense Oct 4, 2022
